A Non-Interventional, Post-Marketing Surveillance Phase IV Study to Asses the Efficacy and Safety of Telmisartan, With the Special Attention on the Influence of Telmisartan on Selected Metabolic Parameters of Patients.
Latest Information Update: 11 Feb 2010
At a glance
- Drugs Telmisartan (Primary)
- Indications Hypertension
- Focus Adverse reactions; Therapeutic Use
- Acronyms METABOLIC
- Sponsors Bayer
- 26 Jan 2010 Actual number of patients (5448) added as reported by ClinicalTrials.gov record.
- 26 Jan 2010 Actual number of patients (5448) added as reported by ClinicalTrials.gov record.
- 26 Jan 2010 Actual end date (1 Nov 2009) added as reported by ClinicalTrials.gov record.